American Journal of Cardiology
Volume 99, Issue 12, Supplement , Pages S4-S20 , 18 June 2007

Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

  • David C. Goff Jr., MD, PhD

      Affiliations

    • Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
    • Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
    • Corresponding Author InformationAddress for reprints: David C. Goff, Jr, MD, PhD, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157-1063.
    • ,
  • Hertzel C. Gerstein, MSc, MD

      Affiliations

    • Department of Medicine and the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
    • ,
  • Henry N. Ginsberg, MD

      Affiliations

    • Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
    • ,
  • William C. Cushman, MD

      Affiliations

    • Memphis Veterans Affairs Medical Center, Memphis, Tennessee, USA
    • ,
  • Karen L. Margolis, MPH, MD

      Affiliations

    • Berman Center for Outcomes & Clinical Research, Hennepin County Medical Center, Minneapolis, Minnesota, USA
    • ,
  • Robert P. Byington, MPH, PhD

      Affiliations

    • Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
    • ,
  • John B. Buse, MD, PhD

      Affiliations

    • Division of General Medicine and Clinical Epidemiology, Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA
    • ,
  • Saul Genuth, MD

      Affiliations

    • Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
    • ,
  • Jeffrey L. Probstfield, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA
    • ,
  • Denise G. Simons-Morton, MD, PhD

      Affiliations

    • Clinical Applications and Prevention Branch, Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.
    • ,
  • ACCORD Study Group

      Affiliations

    • A complete list of the members of the ACCORD Study Group is included in the Appendix.

References 

  1. Savage PJ. Cardiovascular complications of diabetes mellitus (what we know and what we need to know about their prevention). Ann Intern Med. 1996;124(pt 2):123–126
  2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444
  3. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241:2035–2038
  4. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. BMJ. 1983;287:867–870
  5. Barrett-Connor E, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? (The Rancho Bernardo Study). JAMA. 1991;265:627–631
  6. Goldbourt U, Yaari S, Medalie JH. Factors predictive of long-term coronary heart disease mortality among 10059 male Israeli civil servants and municipal employees: a 23 year mortality follow-up in the Israeli Ischemic Heart Disease Study. Cardiology. 1993;82:100–121
  7. Manson JE, Coldlitz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Int Med. 1991;151:1141–1147
  8. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234
  9. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In:  Harris MI,  Cowie CC,  Stern MS,  Boyko EJ,  Reiber GE,  Bennett PH editor. Diabetes in America. 2nd ed.. Washington, DC: National Institutes of Health; 1995;p. 429–448
  10. Morrish NJ, Stevens LK, Fuller JH, Keen H, Jarrett RJ. Incidence of macrovascular disease in diabetes mellitus: the London follow-up to the WHO Multinational Study of Vascular Disease in Diabetics. Diabetologia. 1991;34:584–589
  11. ETDRS [Early Treatment of Diabetic Retinopathy Study] Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus (Early Treatment of Diabetic Retinopathy Study report 14). JAMA. 1992;266:1292–1300
  12. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Eight to nine year mortality in known non-insulin dependent diabetes and controls. Kidney Int. 1992;42:731–735
  13. Neil A, Hawkins M, Potok M, Thorogood M, Cohen DA, Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care. 1993;16:996–1003
  14. HOPE [Heart Outcomes Prevention Evaluation] Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and Micro-HOPE substudy. Lancet. 2000;355:253–259
  15. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291–1297
  16. Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D’Agostino RB, et al. Trends in cardiovascular complications of diabetes. JAMA. 2004;292:2495–2499
  17. Booth GL, Kapral MK, Fung K, Tu JV. Recent trends in cardiovascular complications among men and women with and without diabetes. Diabetes Care. 2006;29:32–37
  18. Behar S, Boyko EJ, Reicher-Reiss H, Goldbourt U. Ten year survival after acute myocardial infarction: comparison of patients with and without diabetes. Am Heart J. 1997;133:290–296
  19. Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol. 1997;30:171–179
  20. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102:1014–1019
  21. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393
  22. Moss SE, Klein R, Klein BEK, Meuer SM. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med. 1994;154:2473–2479
  23. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43:960–967
  24. Andersson DKG, Svardsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care. 1995;18:534–543
  25. Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving H-H. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes. 1995;44:1303–1309
  26. Agewall S, Wikstrand J, Ljungman S, Fagerberg B Risk Factor Intervention Study Group. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Am J Cardiol. 1997;80:164–169
  27. Turner RC. The UK Prospective Diabetes Study: a review. Diabetes Care. 1998;21(suppl):C35–C38
  28. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality: the San Antonio Heart Study. Diabetes Care. 1998;21:1167–1172
  29. Hadden DR, Patterson CC, Atkinson AB, Kennedy L, Bell PM, McCance DR, et al. Macrovascular disease and hyperglycaemia: 10-year survival analysis in type 2 diabetes mellitus (The Belfast Diet Study). Diabet Med. 1997;14:663–672
  30. Fu CC, Chang CJ, Tseng CH, Chen MS, Kao CS, Wu TJ, et al. Development of macrovascular diseases in NIDDM patients in northern Taiwan: a 4-yr follow-up study. Diabetes Care. 1993;16:137–143
  31. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  32. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 1997;46:1354–1359
  33. Gerstein HC, Malmberg KA, Capes S, Yusuf S. Cardiovascular diseases. In:  Gerstein HC,  Haynes RB editor. Evidence-Based Diabetes Care. Hamilton, Ontario, Canada: BC Decker; 2001;p. 488–514
  34. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421–431
  35. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233–240
  36. Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. J Am Coll Cardiol. 1999;33:612–619
  37. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet. 1996;347:949–950
  38. Gerstein HC. Glucose: a continuous risk factor for cardiovascular disease. Diabet Med. 1997;14(suppl):S25–S31
  39. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21:360–367
  40. Bjornholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death (Results from a 22-year follow-up of healthy nondiabetic men). Diabetes Care. 1999;22:45–49
  41. Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev. 1998;19:583–592
  42. Gerstein HC, Capes SE. Dysglycemia: a key cardiovascular risk factor. Semin Vasc Med. 2002;2:165–174
  43. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann Intern Med. 2004;141:413–420
  44. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  45. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  46. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–117
  47. Abraira C, Colwell JA, Nuttall F, Sawin CT, Henderson W, Comstock JP, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Arch Intern Med. 1997;157:181–188
  48. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57–65
  49. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650–661
  50. Genuth S. Exogenous insulin administration and cardiovascular risk in NIDDM and IDDM. Ann Intern Med. 1996;124:104–109
  51. Lawson M, Gerstein HC, Tsui E, Zinman B. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes: a systematic review and meta-analysis. Diabetes Care. 1999;22(suppl):B35–B39
  52. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999;99:2626–2632
  53. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653
  54. Gerstein HC, Capes S. Advantages and perceived disadvantages of insulin therapy for patients with type 2 diabetes. Can J Diabetes Care. 1999;23(suppl):S93–S96
  55. Smits P, Thien T. Cardiovascular effects of sulphonylurea derivatives: implications for the treatment of NIDDM?. Diabetologia. 1995;38:116–121
  56. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281–303
  57. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  58. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  59. Grundy SM. Diabetes and coronary risk equivalency: what does it mean?. Diabetes Care. 2006;29:457–460
  60. Sigurdsson G, Nicoll A, Lewis B. Metabolism of very low density lipoproteins in hyperlipidemia: studies of apolipoprotein B kinetics in man. Eur J Clin Invest. 1976;6:167–177
  61. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very-low-density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes. 1982;31:217–225
  62. Ginsberg H, Grundy SM. Effect of caloric restriction on very low density lipoprotein triglyceride metabolism in subjects with diabetes mellitus. Diabetologia. 1982;23:421–425
  63. Howard BV, Reitman JS, Vasquez B, Zech L. Very-low density lipoprotein triglyceride metabolism in non-insulin-dependent diabetes mellitus: relationship to plasma insulin and free fatty acids. Diabetes. 1983;32:271–276
  64. Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states. Diabetes Care. 1991;14:839–855
  65. Hollenbeck CB, Chen Y-D, Greenfield MS, Lardinois CK, Reaven GM. Reduced plasma high density lipoprotein-cholesterol concentrations need not increase when hyperglycemia is controlled with insulin in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1986;62:605–608
  66. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Diabetes blood lipids and the role of obesity in coronary heart disease risk for women: the Framingham study. Ann Intern Med. 1977;87:393–397
  67. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb. 1992;2:1496–1502
  68. Reaven GM, Chen Y-D, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest. 1993;92:141–146
  69. LRC-CPPT Investigators. The Lipid Research Clinics Coronary Primary Prevention Trial results (I. Reduction in incidence of coronary heart disease). JAMA. 1984;251:351–364
  70. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  71. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 1998;98:2513–2519
  72. The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  73. Hoogwerf BJ, Waness A, Cressman M, Canner J, Campeau L, Domanski M, et al. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial. Diabetes. 1999;48:1289–1294
  74. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287:3215–3222
  75. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  76. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  77. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630
  78. WOSCOPS Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440–1445
  79. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. [Air Force/Texas Coronary Atherosclerosis Prevention Study] JAMA. 1998;279:1615–1622
  80. Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, et al Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care. 2005;28:1151–1157
  81. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696
  82. Vijan S, Hayward RA American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004;140:650–658
  83. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. [published correction appears in Lancet 2005;366:1358] Lancet. 2005;366:1267–1278
  84. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  85. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999;159:2661–2667
  86. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007
  87. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29:1220–1226
  88. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia (Safety of treatment, changes in risk factors, and incidence of coronary heart disease). N Engl J Med. 1987;317:1237–1245
  89. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905–910
  90. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410–418
  91. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21–27
  92. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD [Fenofibrate Intervention and Event Lowering in Diabetes] study): randomised controlled trial. Lancet. 2005;366:1849–1861
  93. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585–2590
  94. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI [Simvastatin Plus Fenofibrate for Combined Hyperlipidemia] trial). Am J Cardiol. 2005;95:462–468
  95. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS [United Kingdom Prospective Diabetes Study] 36): prospective observational study. BMJ. 2000;321:412–419
  96. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 1997;157:2413–2446
  97. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276:1886–1892
  98. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Autikainen R, Bulpitt CJ, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677–684
  99. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762
  100. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998;317:703–713
  101. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645–652
  102. Zanchetti A, Hansson L, Clement D, Elmfeldt D, Julius S, Rosenthal T, et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers?. J Hypertens. 2003;21:797–804
  103. Schrier RW, Estacio RO, Jeffers B. Appropriate Blood Pressure Control in NIDDM (ABCD) trial. Diabetologia. 1996;39:1646–1654
  104. Estacio RO, Jeffers BW, Gifford N, Schrier RW. The effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(suppl):B54–B64
  105. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410–1419
  106. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus. [position statement] Diabetes Care. 2003;26(suppl):S51–S61
  107. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823–828
  108. American Diabetes Association. Smoking and diabetes. Diabetes Care. 2003;26(suppl):S89–S91
  109. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106
  110. Johnson ES, Lanes SF, Wentworth CE, Satterfield MH, Abebe BL, Dicker LW. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med. 1999;159:1248–1253
  111. Steering Committee of the Physicians’ Health Study Research Group. Final report of the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321:129–135
  112. American Diabetes Association. Aspirin therapy in diabetes. [position statement] Diabetes Care. 2003;26(suppl):S87–S88
  113. Colwell JA. Aspirin therapy in diabetes. [technical review] Diabetes Care. 1997;20:1767–1771
  114. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  115. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med. 1996;156:286–289
  116. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med. 1998;128:982–988
  117. ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99(suppl):21i–33i

 This work was supported by Contract Nos. N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184, IAA #Y1-HC-9035, and IAA #Y1-HC-1010 from the National Heart, Lung, and Blood Institute (NHLBI), with additional support from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Eye Institute (NEI), the National Institute on Aging (NIA), and the Centers for Disease Control and Prevention (CDC). General Clinical Research Centers provide support at many sites.

PII: S0002-9149(07)00437-7

doi: 10.1016/j.amjcard.2007.03.002

American Journal of Cardiology
Volume 99, Issue 12, Supplement , Pages S4-S20 , 18 June 2007

Article Tools